Sanofi Medley Farmaceutica Ltda Pharmaceutical Import Profile — Brazil (DGFT 2022–2026)

Name: Sanofi Medley Farmaceutica Ltda Pharmaceutical Import Records from India — 2 Products, $6.4M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Sanofi Medley Farmaceutica Ltda — Pharmaceutical Importer Profile (2026) | 2 Products, $6.4M Trade | TransData Nexus

Sanofi Medley Farmaceutica Ltda

Pharmaceutical Importer · Brazil · Cardiovascular Focus · $6.4M Total Trade · DGFT Verified

Sanofi Medley Farmaceutica Ltda is a pharmaceutical importer based in Brazil with a total trade value of $6.4M across 2 products in 1 therapeutic categories. Based on 192 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Sanofi Medley Farmaceutica Ltda sources from 8 verified Indian suppliers, with Dr.reddy's Laboratories Limited accounting for 57.5% of imports.

Sanofi Medley Farmaceutica Ltda — Import Portfolio & Supplier Network

Sanofi Medley Farmaceutica Ltda import network — 2 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Sanofi Medley Farmaceutica Ltda?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Dr.reddy's Laboratories Limited	$6.6M	241	57.5%
Intas Pharmaceuticals Limited	$1.6M	50	14.3%
Cipla Limited

What Formulations Does Sanofi Medley Farmaceutica Ltda Import?

Formulation	Value	Ships
Omeprazole plt 8	$521.2K	20
Omeprazole plt	$414.7K	16
Ondansetron 4MG tabor bl 10 m24	$306.6K	8
Succinato de metoprolol 50 MG 30's Pack(49392 x 30's Pack) (as per invoice)	$240.3K	5
Pharma drugs & medi apixabana 5MG	$235.3K	5
Ondansetron 8MG tabor bl 10 m24	$202.6K	6
Pharma drugs & medi apixabana 5MG 6x10t (sanofi-brazi) as per	$200.0K	4
Succinato de metoprolol 50MG	$195.2K	4
Lansoprazole pellets	$168.5K	12
Pharma drugs & medi apixabana 2.5MG 6x10t (sanofi-brazi) as per	$162.1K	8
Pharma drugs & medi apixabana 5MG 6x10t(sanofi-brazi) as per	$147.4K	3
Succinato de metoprolol 50MG (49392x30'spack) (as per invoice)	$145.6K	3
Succinato de metoprolol 50 MG (49392 x 30's Pack) (as per invoice)	$141.8K	3
Succinato de metoprolol 25 MG (98352x30s Pack) (as per invoice)	$138.7K	7
Succinato de metoprolol 25 MG (98208 x 30's Pack) (as per invoice)	$138.4K	5

Sanofi Medley Farmaceutica Ltda imports 230 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 2 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Metoprolol	Cardiovascular	$4.7M	146	0.6%	14
2	Apixaban	Cardiovascular	$1.7M	46	1.0%	16

Sanofi Medley Farmaceutica Ltda imports 2 pharmaceutical products across 1 categories into Brazil totaling $6.4M.

Sanofi Medley Farmaceutica Ltda — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Sanofi Medley Farmaceutica Ltda is a Brazilian pharmaceutical company specializing in the manufacturing and distribution of medicinal products. Established on January 19, 2009, in Itapevi, São Paulo, the company operates as a Sociedade Empresária Limitada (Limited Liability Company) under the CNPJ 10.588.595/0001-00. (cnpj.biz) It is a subsidiary of Sanofi, a global healthcare leader headquartered in France. Sanofi Medley Farmaceutica Ltda plays a significant role in Brazil's pharmaceutical distribution network, focusing on the production and wholesale distribution of pharmaceutical formulations.

2Distribution Network

Sanofi Medley Farmaceutica Ltda maintains a robust distribution network across Brazil, with multiple facilities in key locations. The company's main office is situated in Itapevi, São Paulo. Additional facilities include a branch in Campinas, São Paulo, and a distribution center in Guarulhos, São Paulo. (cnpj.biz) These strategically located warehouses enable efficient logistics and nationwide coverage, ensuring timely delivery of pharmaceutical products to various regions within Brazil.

3Industry Role

Sanofi Medley Farmaceutica Ltda operates primarily as a pharmaceutical manufacturer and wholesaler within Brazil's supply chain. The company focuses on the production of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections, which are then distributed to various healthcare providers, pharmacies, and hospitals across the country. This role positions Sanofi Medley Farmaceutica Ltda as a key player in ensuring the availability of essential medications to meet the healthcare needs of the Brazilian population.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Sanofi Medley Farmaceutica Ltda

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Sanofi Medley Farmaceutica Ltda's sourcing strategy exhibits a high degree of concentration, with a significant portion of its pharmaceutical imports originating from India. Between 2022 and 2026, the company imported finished pharmaceutical formulations totaling $6.4 million USD from India, encompassing 192 shipments. The top five products imported include Metoprolol ($4.7 million, Rank #14, 0.6% share) and Apixaban ($1.7 million, Rank #16, 1.0% share). This concentration indicates a strategic choice to leverage India's competitive manufacturing capabilities and cost advantages.

The shipment data reveals a stable relationship with Indian suppliers, as evidenced by the consistent volume of imports over the years. The primary suppliers include DR.REDDY'S LABORATORIES LIMITED ($6.6 million, 241 shipments, 57.5%), INTAS PHARMACEUTICALS LIMITED ($1.6 million, 50 shipments, 14.3%), and CIPLA LIMITED ($1.4 million, 222 shipments, 11.9%). This diversified supplier base within India suggests a strategic approach to mitigate risks associated with single-source dependency while maintaining cost-effectiveness.

2Supply Chain Resilience

Sanofi Medley Farmaceutica Ltda's supply chain resilience is bolstered by its diversified supplier base within India, encompassing eight unique suppliers. This diversification reduces the risk of disruption from any single supplier. The company's focus on finished pharmaceutical formulations, rather than raw APIs or bulk drugs, indicates a preference for suppliers with established manufacturing capabilities and adherence to international quality standards. While specific details regarding backup suppliers and shipping route exposure are not available, the existing supplier diversity suggests a proactive approach to ensuring supply chain continuity.

Importing Pharmaceuticals into Brazil — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Brazil

1Regulatory Authority & Framework

In Brazil, the National Health Surveillance Agency (ANVISA) is the primary regulatory authority overseeing the pharmaceutical sector. ANVISA is responsible for the registration, inspection, and monitoring of pharmaceutical products to ensure public health safety. Key legislation governing pharmaceutical imports includes the Brazilian Health Regulatory Agency Act and the National Health Surveillance Agency Act, which outline the requirements for importing and distributing pharmaceutical products within Brazil. The marketing authorization pathway for Indian generics involves obtaining ANVISA approval, which includes submitting a comprehensive dossier demonstrating the product's quality, safety, and efficacy.

2Import Licensing & GMP

Import licensing requirements for pharmaceutical products in Brazil necessitate that foreign manufacturers obtain ANVISA approval before exporting to the Brazilian market. This process includes providing evidence of Good Manufacturing Practice (GMP) compliance, typically through certificates such as EU GMP, WHO GMP, or PIC/S. Indian exporters must ensure that their manufacturing facilities are certified by recognized authorities to meet ANVISA's stringent standards. Additionally, wholesale distribution authorization is required for entities involved in the distribution of pharmaceutical products within Brazil, ensuring that all intermediaries in the supply chain adhere to regulatory standards.

Sanofi Medley Farmaceutica Ltda — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Sanofi Medley Farmaceutica Ltda's focus on cardiovascular medications, particularly Metoprolol and Apixaban, aligns with the high prevalence of cardiovascular diseases in Brazil. The decision to import these specific therapeutic areas is driven by market demand for effective and affordable treatments for hypertension and thromboembolic disorders. By sourcing these products from India, the company leverages cost advantages while maintaining product quality, thereby meeting the healthcare needs of the Brazilian population.

2Sourcing Profile

Sanofi Medley Farmaceutica Ltda's sourcing strategy emphasizes the procurement of generic drugs, focusing on finished pharmaceutical formulations. This approach allows the company to offer a diverse range of products at competitive prices. India's well-established pharmaceutical manufacturing sector, with its adherence to international quality standards and cost-effective production capabilities, makes it a preferred sourcing destination for Sanofi Medley Farmaceutica Ltda.

3Market Positioning

Based on its product mix, Sanofi Medley Farmaceutica Ltda serves the wholesale distribution segment of the Brazilian pharmaceutical market. By importing and distributing a range of cardiovascular medications, the company supplies hospitals, clinics, and pharmacies with essential treatments, thereby playing a crucial role in the healthcare supply chain.

Seller's Guide — How to Become a Supplier to Sanofi Medley Farmaceutica Ltda

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to collaborate with Sanofi Medley Farmaceutica Ltda, especially if they can offer high-quality products that meet ANVISA's regulatory standards. Gaps in the company's current sourcing include potential expansion into other therapeutic areas and the introduction of innovative formulations. Indian exporters can explore these opportunities by ensuring compliance with Brazilian regulations and demonstrating the value proposition of their products.

2Requirements & Qualifications

Indian exporters aiming to supply Sanofi Medley Farmaceutica Ltda and the Brazilian market must obtain GMP certifications from recognized authorities such as EU GMP, WHO GMP, or PIC/S. Additionally, they must ensure that their products meet ANVISA's quality, safety, and efficacy standards, including compliance with labeling and serialization requirements. Establishing a local presence or partnership within Brazil can also facilitate smoother market entry and distribution.

3How to Approach

Frequently Asked Questions — Sanofi Medley Farmaceutica Ltda

What products does Sanofi Medley Farmaceutica Ltda import from India?

Sanofi Medley Farmaceutica Ltda imports 2 pharmaceutical products across 1 categories. Top imports: Metoprolol ($4.7M), Apixaban ($1.7M).

Who supplies pharmaceuticals to Sanofi Medley Farmaceutica Ltda from India?

Sanofi Medley Farmaceutica Ltda sources from 8 verified Indian suppliers. The primary supplier is Dr.reddy's Laboratories Limited (57.5% of imports, $6.6M).

What is Sanofi Medley Farmaceutica Ltda's total pharmaceutical import value?

Sanofi Medley Farmaceutica Ltda's total pharmaceutical import value from India is $6.4M, based on 192 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Sanofi Medley Farmaceutica Ltda focus on?

Sanofi Medley Farmaceutica Ltda imports across 1 categories. The largest: Cardiovascular (100.0%).

Get Full Sanofi Medley Farmaceutica Ltda Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.